Related Experiment Video
Updated: Apr 19, 2026
04:25
Intratibial Osteosarcoma Cell Injection to Generate Orthotopic Osteosarcoma and Lung Metastasis Mouse Models
Published on: October 28, 2021
12.2K
Complementary genomic approaches highlight the PI3K/mTOR pathway as a common vulnerability in osteosarcoma
Jennifer A Perry1, Adam Kiezun2, Peter Tonzi1
1Department of Pediatric Oncology, Dana-Farber/Boston Children's Cancer and Blood Disorders Center, Boston, MA 02215;
Summary
Osteosarcoma, a common bone cancer, shows limited treatment advances. Genomic analysis reveals the phosphatidylinositol 3-kinase/mammalian target of rapamycin (PI3K/mTOR) pathway as a key vulnerability for new therapies.
Area of Science:
- Oncology
- Genomics
- Molecular Biology
Background:
- Osteosarcoma is the most common primary bone tumor.
- Despite its prevalence, treatment and survival rates for osteosarcoma have seen no significant improvement in 30 years.
Purpose of the Study:
- To identify genomic alterations and therapeutic vulnerabilities in osteosarcoma.
- To explore potential new treatment strategies for this challenging cancer.
Main Methods:
- Whole-exome, whole-genome, and RNA-sequencing of 59 osteosarcoma/normal tumor pairs.
- Analysis of mutation rates, somatic rearrangements, and genomic instability.
- Pathway analysis, heuristic algorithms, comparative oncology, and shRNA screening to identify therapeutic targets.
Main Results:
- TP53 gene mutations were frequent across all samples.
- High rates of somatic rearrangements and localized hypermutation were observed.
- The phosphatidylinositol 3-kinase/mammalian target of rapamycin (PI3K/mTOR) pathway was identified as a central vulnerability.
Conclusions:
- The PI3K/mTOR pathway represents a promising therapeutic target for osteosarcoma.
- Osteosarcoma cell lines demonstrate sensitivity to PI3K/mTOR pathway inhibition in vitro and in vivo.
Related Concept Videos
01:22PI3K/mTOR/AKT Signaling Pathway
6.5K
The mammalian target of rapamycin (mTOR) is a serine/threonine kinase that regulates growth, proliferation, and cell survival in response to hormones, growth factors, or nutrient availability. This kinase exists in two structurally and functionally distinct forms: mTOR complex 1 (mTORC1) and mTOR complex 2 (mTORC2). The first form (mTORC1) is composed of a rapamycin-sensitive Raptor and proline-rich Akt substrate, PRAS40. In contrast, mTORC2 consists of a...
6.5K
03:03mTOR Signaling and Cancer Progression
5.1K
The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
The mTOR pathway or the...
5.1K
03:03mTOR Signaling and Cancer Progression
1.8K
1.8K
01:07MAPK Signaling Cascades
9.5K
Mitogen-activated protein kinase, or MAPK pathway, activates three sequential kinases to regulate cellular responses such as proliferation, differentiation, survival, and apoptosis. The canonical MAPK pathway starts with a mitogen or growth factor binding to an RTK. The activated RTKs stimulate Ras, which recruits Raf or MAP3 Kinase (MAPKKK), the first kinase of the MAPK signaling cascade. Raf further phosphorylates and activates MEK or MAP2 Kinases (MAPKK), which in turn phosphorylates MAP...
9.5K
01:19Interactions Between Signaling Pathways
8.0K
Signaling cascades usually lack linearity. Multiple pathways interact and regulate one another, allowing cells to integrate and respond to diverse environmental stimuli.
Convergence and divergence, and cross-talk between signaling pathways
Two distinct signaling pathways can converge on a single functional unit, which may either be a single protein or a complex of proteins. The response is either functionally distinct or synergistic between the two pathways but different from the response...
Convergence and divergence, and cross-talk between signaling pathways
Two distinct signaling pathways can converge on a single functional unit, which may either be a single protein or a complex of proteins. The response is either functionally distinct or synergistic between the two pathways but different from the response...
8.0K
01:20The JAK-STAT Signaling Pathway
14.2K
Several cytokine receptors have tightly bound Janus kinase or JAK proteins attached at their cytosolic tail. Small signaling molecules such as cytokines, growth hormones, or prolactins bind to the cytokine receptors and initiate their dimerization. The dimerization brings the cytosolic JAKs together that trans-phosphorylate and activates each other. The activated JAKs now phosphorylate cytosolic tails of the cytokine receptors, which serve as binding sites for adaptor proteins such as SH2...
14.2K